Stool Microbiome Profiling of Patients with Metastatic Renal Cell Carcinoma Receiving Anti–PD-1 Immune Checkpoint Inhibitors

Salgia, Nicholas; Bergerot, Paulo Gustavo; Maia, Manuel Caitano; Dizman, Nazlı; Hsu, JoAnn; Gillece, John D.; Folkerts, Megan; Reining, Lauren; Trent, Jeffrey M.; Highlander, Sarah K.; Pal, Sumanta K.

doi:10.1016/j.eururo.2020.07.011

Cited by 133 publications

(122 citation statements)

References 10 publications

Supporting

Mentioning

107

Contrasting

Unclassified

Order By: Relevance

“…Functional analysis using Kyoto Encyclopedia of Genes and Genomes (KEGG) identified several pathways which were over-represented in the resulting gut microbiome of the responders like cellulose and pectin metabolism as well as methanogenesis pathways, indicating an improved energy metabolism might be contributing to the improved response to ICBs (194). Salgia et al analyzed sequential stool samples from patients with metastatic RCC on nivolumab or nivolumab+ipilimumab combination and observed that the relative abundance of A. muciniphila increased in patients deriving clinical benefit from ICB whereas it decreased in some of the non-responders (198). These findings hint at the existence of host and/or tumor specific microbial regulatory pathways which may attempt to dynamically modulate the resident commensals to facilitate or antagonize the anti-tumor immune response.…”

Section: Effect Of Icbs On Gut Microbiome Compositionmentioning

confidence: 99%

New Insights Into the Cancer–Microbiome–Immune Axis: Decrypting a Decade of Discoveries

et al. 2021

View full text Add to dashboard Cite

The past decade has witnessed groundbreaking advances in the field of microbiome research. An area where immense implications of the microbiome have been demonstrated is tumor biology. The microbiome affects tumor initiation and progression through direct effects on the tumor cells and indirectly through manipulation of the immune system. It can also determine response to cancer therapies and predict disease progression and survival. Modulation of the microbiome can be harnessed to potentiate the efficacy of immunotherapies and decrease their toxicity. In this review, we comprehensively dissect recent evidence regarding the interaction of the microbiome and anti-tumor immune machinery and outline the critical questions which need to be addressed as we further explore this dynamic colloquy.

show abstract

Section: Effect Of Icbs On Gut Microbiome Compositionmentioning

confidence: 99%

New Insights Into the Cancer–Microbiome–Immune Axis: Decrypting a Decade of Discoveries

et al. 2021

View full text Add to dashboard Cite

show abstract

“…After treating with nivolumab or nivolumab plus ipilimumab, stool samples were collected and analyzed from mRCC patients, the result revealed that several bacteria are related to clinical benefit. They also found that a better treatment outcome is associated with high microbial diversity ( 72 ). The mechanism of Akkermansia muciniphila which promotes the effect of ICIs might be related to inosine ( Figure 2 ), Akkermansia muciniphila can produce inosine in vitro in ICIs-treated tumors.…”

Section: Gut Microbiota Is Associated With the Effect Of Ici Immunotherapymentioning

confidence: 99%

Modulation of Gut Microbiota to Enhance Effect of Checkpoint Inhibitor Immunotherapy

Wang

Zheng

et al. 2021

Front. Immunol.

View full text Add to dashboard Cite

Accumulating evidence demonstrated the crucial role of gut microbiota in many human diseases, including cancer. Checkpoint inhibitor therapy has emerged as a novel treatment and has been clinically accepted as a major therapeutic strategy for cancer. Gut microbiota is related to cancer and the effect of immune checkpoint inhibitors (ICIs), and supplement with specific bacterial species can restore or enhance the responses to the ICIs. Namely, specified bacteria can serve as the biomarkers for distinguishing the patient who will respond to ICIs and determine the effectiveness of ICIs, as well as predicting the efficacy of checkpoint inhibitor immunotherapy. Regardless of the significant findings, the relationship between gut microbiota and the effect of ICIs treatment needs a more thorough understanding to provide more effective therapeutic plans and reduce treatment complication. In this review, we summarized the role of gut microbiota played in immune system and cancer. We mainly focus on the relationship between gut microbiota and the checkpoint inhibitor immunotherapy.

show abstract

“…The influence of microbiota was not only restricted to melanoma patients. In the context of renal cell carcinoma, the abundance of Akkermansia muciniphila in stool at the time of diagnosis was associated with better response to CPIs [ 77 ]. Similar findings were also reported by Routy et al, who assessed stool samples from patients with renal cell and non-small cell lung carcinoma [ 30 ].…”

Section: Gut Microbiota’s Influence On Patients’ Response and Sensitivity To Cpismentioning

confidence: 99%

The Role of Gut Microbiota in Overcoming Resistance to Checkpoint Inhibitors in Cancer Patients: Mechanisms and Challenges

Bouferraa

Chedid

Amhaz

et al. 2021

IJMS

View full text Add to dashboard Cite

The introduction of immune checkpoint inhibitors has constituted a major revolution in the treatment of patients with cancer. In contrast with the traditional cytotoxic therapies that directly kill tumor cells, this treatment modality enhances the ability of the host’s immune system to recognize and target cancerous cells. While immune checkpoint inhibitors have been effective across multiple cancer types, overcoming resistance remains a key area of ongoing research. The gut microbiota and its role in cancer immunosurveillance have recently become a major field of study. Gut microbiota has been shown to have direct and systemic effects on cancer pathogenesis and hosts anti-tumor immune response. Many studies have also shown that the host microbiota profile plays an essential role in the response to immunotherapy, especially immune checkpoint inhibitors. As such, modulating this microbial environment has offered a potential path to overcome the resistance to immune checkpoint inhibitors. In this review, we will talk about the role of microbiota in cancer pathogenesis and immune-system activity. We will also discuss preclinical and clinical studies that have increased our understanding about the roles and the mechanisms through which microbiota influences the response to treatment with immune checkpoint inhibitors.

show abstract

Stool Microbiome Profiling of Patients with Metastatic Renal Cell Carcinoma Receiving Anti–PD-1 Immune Checkpoint Inhibitors

Cited by 133 publications

References 10 publications

New Insights Into the Cancer–Microbiome–Immune Axis: Decrypting a Decade of Discoveries

New Insights Into the Cancer–Microbiome–Immune Axis: Decrypting a Decade of Discoveries

Modulation of Gut Microbiota to Enhance Effect of Checkpoint Inhibitor Immunotherapy

The Role of Gut Microbiota in Overcoming Resistance to Checkpoint Inhibitors in Cancer Patients: Mechanisms and Challenges

Contact Info

Product

Resources

About